MRC Clinical Trials Unit at UCL
Institute of Clinical Trials & Methodology
90 High Holborn 2nd Floor
* The recommended chemotherapy in ICON6 is carboplatin plus paclitaxel, however treatment with other platinum-based chemotherapy regimens may be permitted, as detailed in section 9.3 in the protocol.
§ Trial Drug (placebo or cediranib) continues for 18 months, or can continue beyond 18 months until disease progression, whichever is sooner. Patients who have not progressed at 18 months from randomisation can continue Trial Drug until progression, if in the opinion of the clinician there is continuing clinical benefit (whilst supply lasts).